Glenmark Specialty, in collaboration with Cosmo Pharmaceuticals, has finalized distribution and license agreements for Winlevi, a clascoterone-based cream, in Europe and South Africa. The exclusive commercialization rights cover 15 EU countries, South Africa, and the UK. Cassiopeia, a Cosmo subsidiary, will handle Centralized Marketing Authorization at the European Medicines Agency, while Glenmark takes charge of product registration in South Africa and the UK. In return, Cassiopeia receives a $5 million upfront payment and double-digit royalties on net sales. Winlevi, approved by the US FDA for acne treatment, introduces a novel mechanism of action, marking a significant development in the acne pharmaceutical landscape. The EU acne market’s substantial growth underscores the strategic importance of this collaboration.
Glenmark Secures Distribution Rights for Winlevi in Europe and South Africa
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2023/09/22103022/Glenmark-860x466.jpg)